Sage Therapeutics Surges 5671.34% in Trading Volume to Rank 403rd as Supernus Pharmaceuticals Acquires for $795 Million

On June 16, 2025, Sage Therapeutics (SAGE) saw a significant surge in trading volume, with a turnover of $249 million, marking a 5671.34% increase from the previous day. This surge placed Sage at the 403rd position in the daily stock market rankings. The stock price of Sage Therapeutics rose by 35.37%, marking the second consecutive day of gains, with a total increase of 37.42% over the past two days.

Supernus Pharmaceuticals has agreed to acquire all outstanding shares of Sage Therapeutics for a purchase price of $561 million. This acquisition is expected to accelerate mid- to long-term revenue and cash flow growth for Supernus, further diversifying its revenue base. The deal is anticipated to close in the third quarter of this year.

Sage Therapeutics CEO Barry Greene expressed confidence that the acquisition maximizes value for shareholders. He also thanked the Sage team for their commitment to brain health and improving patient lives, looking forward to the next chapter with Supernus.

Supernus Pharmaceuticals is acquiring Sage Therapeutics for up to $795 million, aiming to transform Sage's postpartum depression drug into a standard of care. This acquisition follows a comprehensive strategic review by Sage's Board of Directors, marking a significant turnaround for the biotech company after years of setbacks.